The failure of the MS therapeutics IFN-beta, GLAT and NAT in many of our patients supports the view that classical MS and AQP4- or MOG-IgG-associated disorders differ in terms of immunopathogenesis. The gene discussed is MOG; the disease is myeloid sarcoma.